Treatments available to women with locally advanced breast cancer are unsatisfactory, since most patients succumb to metastatic spread. Therefore, there is a need to devise novel therapeutic combinations that effectively inhibit metastatization and to test them in animal models of breast cancer showing strong similarities with their human counterpart, including the ability to give rise to metastases. With these considerations in mind, tamoxifen (TAM), 4-hydrotamoxifen (4-HT) or liposome-complexed DNA constructs coding for antiangiogenic/anti-invasion proteins (angiostatin, TIMP-2, IFN-a 1 , sFLT-1) were individually administered to MMTVneu transgenic mice. Significant inhibition of primary tumor growth was obtained with TAM (40% inhibition, P¼0.049), angiostatin (85% inhibition, P¼0.001) and TIMP-2 (60% inhibition, P¼0.015). No lung metastasis was observed in any of these treated mice at 5 months, compared with a rate of 70% in control groups. These observations were the basis for designing a combined treatment with all these compounds. The association of angiostatin, TIMP-2 and TAM was greatly effective at the primary tumor level (90% inhibition, P¼0.01). Moreover, all the mice treated with this association were metastasis free at a time point (6 months) in which seven out of nine control mice were either dead from disseminated cancer or showed lung metastasis. This combined therapy could become an important component of anticancer therapy in humans.
Introduction
Human breast cancer cells are susceptible to many endocrine and chemotherapy agents, but protocols for women with advanced disease are still unsatisfactory and metastatic breast cancer is still associated with a high rate of treatment failure and mortality. 1 For this reason, new protocols are being evaluated in clinical trials, and the availability of an experimental model to test single and combination therapies could be priceless.
Unfortunately, many promising therapeutic approaches in mouse do not perform well in humans. The reason for this could lie in the differences between rodent and human breast tumor biology or in the different endocrine milieu affecting the response to therapy. However, favorable responses that are not replicated in humans also depend on the system adopted, since most conventional and gene therapy trials in experimental oncology are performed on transplantable tumor models, which are now recognized to be, to a great extent, artificial and not representative of human pathology, 2, 3 where a single cancer cell adapts to a hostile environment, escapes immune recognition, acquires further genetic changes, invades surrounding tissues and often leads to metastasis. For these reasons, it has been suggested that tumor eradication in these animal models could be easier than in humans, thus explaining the good therapeutic results that cannot be replicated in humans. This hypothesis has recently been rigorously tested and the results showed that autochthonous breast tumors were resistant to IL-12 treatment, while the same neoplasias grown as transplanted tumors were not. 4 In this regard, it is remarkable that in transgenic mouse models, the results obtained were less spectacular and more comparable to those obtained in current human trials. 5, 6 We have therefore pioneered the use of transgenic mice as models for evaluation of new gene therapy strategies. [6] [7] [8] [9] [10] [11] [12] We have extensively used a transgenic mouse model (MMTVneu) of breast carcinoma, which has many similarities with its human counterpart. Briefly, breast tumors in MMTVneu mice occur spontaneously, overexpress the neu oncogene, escape the immune system, grow in situ and adapt to the microenvironment, recruit vessels, invade the tissues, penetrate the vasculature and give rise to distant metastases. 6, 7 This complex process parallels the human situation much more closely than transplantable tumors and takes place over several months, so that the followup period is not limited to a few weeks as usually is the case with transplantable tumors. In addition, tumors arising in MMTVneu mice bear estrogen receptors, 13 which are present in a subset of human tumors and show chromosomal changes similar to ones found in human breast tumors.
14 Finally, tumors arise in these animals with great reproducibility, since they have been used for almost 10 years in our laboratory without showing changes in the kinetics of tumor formation, and this makes a comparison between new treatments and those previously performed possible. 6 Over the last few years, we have focused on single agent protocols able to inhibit metastatic growth, which is thought to be dependent on the expression of several genes involved in angiogenesis, matrix degradation and tissue reorganization. These included angiostatin, a wellknown and promising inhibitor of angiogenesis, 15, 16 and tissue inhibitor of metalloproteinase-2 (TIMP-2), an inhibitor of matrix metalloproteinases (MMPs), 17 a family of zinc-dependent proteinases which have a role in the degradation of the extracellular matrix components 18, 19 as well as angiogenesis [20] [21] [22] and have been involved in facilitating tumor cell invasion and metastasis.
For these reasons, we decided to investigate other genes involved in these processes, including the soluble form of the VEGF receptor 1 (sFLT-1) and interferon-a 1 (IFN-a 1 ), a member of the type 1 IFN family. [23] [24] [25] These proteins are good candidates for gene delivery because they are produced physiologically, indicating that they are probably not immunogenic, and they are effective extracellularly, which circumvents the need to transduce all tumor cells. In particular, sFLT-1 is considered a decoy receptor able to bind and inactivate VEGF function, thus limiting its trophic effect on endothelium. 25 IFN-a and IFN-b are multifunctional regulatory cytokines involved in the control of cell proliferation and viral infections that also show antiangiogenic activity both in vitro and in vivo. [26] [27] Moreover, IFN-a1 seems more active as an angiostatic drug when administered systemically at relatively low doses. 28 In this paper, we tested the effects of different antiangiogenic/anti-invasion factors administered individually using a gene therapy approach. We also tested the effects of different conventional antiestrogen therapies. However, the ultimate goal of our study was to devise a combined therapy that could be effective on three different parameters: primary tumor growth, metastatic dissemination and survival. We reasoned that only by demonstrating a strong effect on metastasis growth and survival could the anticancer strategy be considered robust. We therefore tested a combination of three agents which performed well as single agents in our system. The positive results obtained with the combination of angiogenesis and metalloproteinase inhibitors with antiestrogenic drugs suggest that this approach is worth trying in humans since it could be easily implemented and may significantly contribute to anticancer therapy.
Results

Single treatments
In single-agent protocols, MMTVneu treated and untreated females were monitored up to 5 months of age. The rationale for this end point has been explained. 6 At this time, the mice were killed, a complete necropsy was performed and the data processed as previously described. 6 Every set of treatments included control untreated mice; 4-11 mice were used in each group (see Table 1 for details).
The release of therapeutic proteins by the expression vectors was tested in vitro by Western blot analysis as detailed in Materials and methods, and the results are shown in Figure 1 . Supernatants from either 293T or KS-IMM cells transiently transfected with pcDNA3.1-TIMP-2, -IFN-a 1 and -sFLT-1 showed a specific immunoreactive band (lanes 1 and 3) , while cells transfected with the control plasmid pcDNA3.1 did not (as shown in lanes 2 and 4 of Figure 1 ). Human TIMP-2 generated a band of about 21 kDa; murine IFN-a 1 and sFLT-1 generated bands of 20 and 110 kDa, respectively. An additional band of lower intensity and about 53 kDa in size was also detected in the supernatant of 293T cells transfected with the pcDNA3.1-sFLT-1 plasmid. The biological activity of angiostatin construct (A3/3) has been previously reported. 6, 11, 12 The presence and expression of therapeutic DNAs in tumors or other mouse tissues was confirmed by PCR and RT-PCR, respectively, as previously described 6, 11 (data not shown).
Evaluation of the effect of single therapies
Tumor weights from each group were compared to each other and to those of controls. To determine whether the delay in tumor growth also reflects on the ability of neoplastic cells to spread to distant sites, a careful examination of lungs in all the treated and control groups was performed. These results are shown in Figure 2a , where the effects of single treatments on tumor growth 7s.e. (black boxes) and on lung metastases (white boxes) are indicated as percentage of controls. For the sake of comparison, the results obtained with related treatments in previous experiments are shown in the same figure ( Figure 2b ). The number of animals used for every group of treatment and the 6 See also Figure 2 .
Combined therapy for breast cancer in the MMTVneu model MG Sacco et al P-value between each single treatment and controls are reported in Table 1 .
In 5-month-old untreated transgenic controls, the average tumor weight for every mammary gland was reproducibly about 1 g (n¼30). This result was reproduced in this new set of control mice (for a total of 28 mice). Consistent with previous data, 6 lung metastases were found in about 70% of control mice.
Tamoxifen (TAM) is a well-known compound with antiestrogenic activity, which has been used both in treatment of disseminated diseases and in prevention of breast cancer. 29 We previously described the efficacy of TAM treatment administered subcutaneously (s.c.) at 20 mg/kg alone or in combination with intraperitoneal (i.p.)-delivered angiostatin gene therapy. 12 We performed a new group of treatments in which TAM was administered i.p. at the same dose. In addition, we also tested the effects of 4-hydrotamoxifen (4-HT), a synthetic molecule described to exert an action similar to TAM at lower doses, 30 with reduced collateral effects, which was administered at 2 mg/kg. At the dosage used, IP 4-HT was not as effective against primary tumors as i.p. TAM, although with both treatments small metastatic nodules were observed in two out of six mice. As we did not detect any metastatic growth in s.c.-delivered TAMtreated mice, 12 it could be possible that the i.p. route of TAM administration is slightly less effective than the s.c. one, although no significant differences were seen with regard to primary tumor growth. TAM has an antiestrogenic effect which could reflect in an inhibition of mammary gland development when used at 3 weeks of age. This raises the possibility that its effect on tumor growth could in part be indirect, via a reduction of mammary cells number or growth rate. To test this possibility, we performed a histological analysis of mammary glands from TAM-treated versus untreated mice. Both the extension of mammary tissue and tubule density was evaluated in five mice. Our analysis showed that the mammary glands from treated mice were indeed less developed, suggesting that the TAM effect might be mediated at least in part by an indirect action. Table 1 .
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We previously described the effects of local and systemic A3/3 gene therapy which showed encouraging results. 6, 11 In this study, we investigated whether angiostatin delivered intravenously (i.v.) to 2-, 3-and 4-month-old MMTVneu females was also effective. As expected, the best results were obtained with early treatments (see Figure 2) , although the results achieved with intratumoral (i.t.) or i.p. administration were clearly superior to those obtained by i.v. administration. However, it is possible that i.v. injection of larger amount of DNA/DOSPER mixture could increase the effect of this administration route.
We have also previously described that TIMP-2 systemic gene therapy (i.p.) causes a partial reduction of primary tumor growth and metastatization. 11 Here we evaluated the effect of local (i.t.) TIMP-2 gene therapy which was more effective (P¼0.015 versus controls) than i.p. therapy. No previous trials were carried out with the last two agents, sFLT-1 and IFN-a 1 . The i.t. sFLT-1 gene therapy had no effect either on local tumor growth or on metastatization. Finally, the IFN-a 1 gene therapy administered systemically reduced the primary tumor growth of about 50% (not significant, P¼0.159), and one out of five treated mice had lung metastases.
Combined therapy
Treatments showing the best effects in terms of inhibition of primary tumor growth and metastatization were selected for use in combined treatment. In particular, i.t. A3/3, 6 i.t. TIMP-2 (present study) and s.c. TAM 12 gave the highest reductions of tumor growth associated with complete inhibition of metastatization when used as single agents. In addition, although some antiangiogenic activity has been described also for TIMP-2 and TAM, 31, 32 these compounds act predominantly through different pathways and therefore their action could be synergic, or at least additive.
A3/3-TIMP-2 combined gene therapy was then performed i.t., alone (four mice) or in combination with s.c. TAM (five mice). TAM treatment was started at 3 weeks, while gene therapy treatment was introduced at 6 weeks. In order to evaluate whether this combination therapy increased the survival rate, treatments were prolonged up to 6 months of age. For this reason, we also included a set of nine control mice to be killed at 6 months. Three of them died between the 5th and 6th month with gross lung metastases (they could not be processed for the evaluation of tumor weight). In total, seven (including the three dead animals) out of nine control mice examined at 6 months had lung metastases. As expected, primary tumor weights in both groups of gene therapy-treated mice were lower than those of control mice, but only the triple treatment reached statistical significance, as shown in Figure 3 . (P¼0.01). However, it must be pointed out that this value is underestimated, since the three dead mice that were not included in the primary tumor weight evaluation had very large tumors.
Moreover, the effect on metastatization was remarkable with both the triple and the double strategy (see detailed analysis in Table 2) ; only a few small metastatic nodules were found in double gene therapy-treated mice, while no metastases were detected in any of the five mice treated with the triple approach. Statistical analysis performed with Fisher's exact test showed that only the results obtained with the triple combination were significantly different from those of controls (P¼0.021). Therefore, our data indicate that combined therapy with these three compounds is not only active against primary tumor growth, but is also effective with Figure 3 Effect of combined treatments evaluated on 6-month-old MMTVneu mice. Mean7s.e. of the percentage of tumor weight with respect to controls (100%) evaluated on 6-month-old transgenic females treated with A3/3 plus TIMP-2 gene therapy alone (four mice) or associated with hormone (TAM) therapy (five mice). In the control group, only six out of nine mice survived until 6 months and were used for the evaluation of tumor weight. regard to metastatic dissemination. In addition, the complete absence of metastasis at 6 months, compared with 33% of deaths in control group, suggests that the response to the triple treatment might also result in prolonged survival.
Histology
Histological examination confirmed the presence of mammary solid carcinomas in all transgenic animals. Uteri from control mice were normal, while endometrial cystic hyperplasia was observed in all the tamoxifentreated animals. These findings are imputable to the effect exerted by tamoxifen on the female reproductive system. 33 On the contrary, the 4-HT-treated group did not show any alteration on the reproductive tract, as expected. All other investigated organs from control and treated mice were normal.
We evaluated the effects of single treatments on vascularization. We observed in general a modest reduction of the vessel density in treated mice compared to control mice but the differences were not statistically significant (data not shown).
Discussion
Combination therapies are widely used in the treatment of breast cancer, both as adjuvant therapy and in patients with advanced disease. 34 The rationale is that the association of agents acting on tumor growth with different mechanisms could have additive or even synergistic effects on tumor cells, without a concomitant increase in toxicity. However, the benefits of a specific combination protocol cannot easily be predicted. In addition, different administration routes have to be taken into consideration. This results in a myriad of possible combinations that must be individually tested, resulting in costly and lengthy clinical trials.
The availability of transgenic animal models reproducing many, if not all, of the features of human cancer would simplify the selection of the best anticancer associations. In the last 10 years we have been using an MMTVneu transgenic model for gene therapy trials and we have shown that it is more representative of the human disease than transplantable tumor models (see Introduction and references therein). The MMTVneu mouse is only one of many breast cancer models that can be used to investigate new treatments and it is probably not representative of all breast adenocarcinomas, as only 30% of human tumors bear abnormalities in ErbB-2 gene. 35 Over the next few years, the contribution of other genes to breast cancer will be identified and the knock-out and knock-in technologies will probably give us new opportunities to create models for different subsets of breast cancer, as recently shown by the findings of breast tumors in Brca1 conditional knockouts 36 and in mice heterozygous for an in-frame three amino-acid deletion in the ATM gene. 37 In the present paper, we built on previous treatment protocols as well as on new experiments with singleagent treatments administered via various routes to select treatments showing the highest inhibition of tumor growth. We devised a combined therapy with three agents that affect tumor growth through different mechanisms. We have shown that an 'old' drug, tamoxifen, can be usefully combined with new ones including, in particular, an antiangiogenic agent (angiostatin, A3/3) and a metalloproteinase inhibitor (TIMP-2), delivered by a gene transfer approach. Although these agents when used alone showed tumor inhibition, their combination resulted in further reduction of primary tumor growth to 10% of that of control mice and completely prevented lung metastatization up to 6 months of age. These figures are better than those obtained with the single agents.
In the present work, we did not find any correlation between tumor inhibition and a reduction in vessel density. There are several explanations for this data, some of which have recently been mentioned in a review by Kerbel and Folkman. 38 First, vessel inhibition could be different in our spontaneous tumors compared to transplantable tumors in which most animal studies with angiogenesis inhibitors have been performed. Second, the current standard approach to count vessels in hot spots may not reflect the real vascularization status of the tumor. Third, microvessel density could increase if, during treatment, tumor cell dropout exceeds capillary dropout, or remain the same if the disappearance of capillaries and tumor cells parallel each other.
In conclusion, based on these results, we suggest that this association is worth trying in humans and that transgenic models could be used for preliminary screening of therapeutic associations involving both conventional and novel strategies such as gene therapy.
Materials and methods
DNA constructs
Constructs containing murine angiostatin (A3/3), and TIMP-2 cDNA have been previously described. 6, 39 Murine IFN-a 1 was obtained by PCR amplification from plasmid LMuIFNa1SN, previously described, The biological effects of A3/3 gene therapy were previously described. 6, 11, 12 Two cell lines were used: 293T cells were derived from human embryonic kidney 41 and were obtained from ATCC. KS-IMM cells were derived from a Kaposi sarcoma biopsy from a kidney-transplanted immunosuppressed male patient as previously reported. 42 The in vitro release of TIMP-2, IFN-a 1 and sFLT-1 products in supernatants of transiently transfected 293T and KS-IMM cells was determined by Western blotting, according to standard protocols. 43 For immunoblotting analysis, the supernatants were Combined therapy for breast cancer in the MMTVneu model MG Sacco et al concentrated 10-fold on Ultrafree columns (Millipore, Bedford, MA, USA) with 10 kDa cutoff. Subsequently, 40 ml aliquots were electrophoresed on 12.5% polyacrylamide gels (10% for sFLT-1), and separated proteins were blotted for 2 h at 400 mA onto a nitrocellulose membrane. The membrane was then saturated with PBS 1% nonfat dry milk (Sigma) as blocking buffer for 3 h at RT, and then stored at À201C until use. Immunoprobing was performed with a 1:1000 dilution of a rabbit mAb against TIMP-2 (Chemicon International, Temecula, CA, USA), a 1:500 dilution of a rabbit antiserum against murine IFN-a 1 (Calbiochem, San Diego, CA, USA), or a 1:500 dilution of a rabbit antiserum against FLT-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by hybridization with a 1:5000 diluted anti-mouse or antirabbit HRP-conjugated antibody (Amersham-Pharmacia, Little Chalfont, UK). Antigens were identified by luminescent visualization using the SuperSignal kit (Pierce, Rockford, IL, USA).
Animals and pathological examination
The production and screening of MMTVneu transgenic mice as well as the histological features of tumors have been previously described. 6, 7 At the end of the 5th month (or the 6th month for combined treatments), mice were killed, tumors were removed, weighed and subjected to molecular and histopathological analyses. Control tumor weight was expressed as 100%7s.e. and the results of treatments were expressed as percentage7s.e. of control tumor weight.
Mammary tumors were classified according to the recommendations of the Annapolis meeting. 44 For a careful examination of metastatic spread to lungs, all lobes of every lung were evaluated on a single histological section. The effect of therapies on metastases was expressed as percentage of mice carrying lung metastases with respect to the total number of mice analyzed in every group.
To evaluate the TAM effect on mammary gland development, five CD-1 mice were treated with TAM i.p. once a week from 3 to 6 weeks of age, when a necropsy was performed. Five untreated, 6 week old CD-1 mice were also killed as controls. From each animal, the second, third and fouth mammary glands were submitted to histological examination for the presence and extension of mammary tissue and for the evaluation of density of tubular structures within the mammary tissue.
Single and combined treatments and route of administration
The following agents were individually evaluated in the present study: TAM and 4-HT were administered i.p.; plasmid-based angiostatin was delivered i.v., TIMP-2 and sFLT-1 were delivered i.t., while IFN-a 1 was injected i.p., as liposome formulations. The choice of these routes complements those adopted in previous studies. In particular, angiostatin has already been investigated i.t. and i.p., while TIMP-2 i.p. and TAM have been studied s.c. 6, 11, 12 Tam, 4-HT and Corn Oil were purchased from SIGMA. TAM and 4-HT stock solutions were prepared according to the manufacturer's instructions and then dissolved in Corn Oil for s.c. treatments (50 ml/mouse) or PBS (GIBCO BRL) for i.p. treatments (100 ml/mouse). TAM was administered at the dose of 20 mg/kg, while 4-HT was administered at 2 mg/kg. Treatments were carried out weekly starting from 3 weeks of age.
Plasmid DNA was prepared as previously described and added to the DOSPER liposomal transfection agent (Roche Diagnostics SpA, Monza, Italy) according to the manufacturer's instructions. For the i.t. treatments, 50 ml of the DOSPER/DNA mixture, containing 2 mg of DNA, was injected i.t. into all the 10 mammary glands of MMTVneu female mice for TIMP-2, while the sFLT-1 construct was injected into mammary glands of one side only, in order to evaluate the local effect of treatment (see Sacco et al 6 for the rationale). Treatments started at 6 weeks of age and were performed every 2 weeks. i.v. treatments with A3/3 were performed weekly with the same DNA/Dosper amount starting from 2, 3 or 4 months of life. IFN-a 1 was administered i.p. weekly, using a mixture of Dosper/DNA containing 6 mg DNA in 100 ml. All treatments were carried out until 5 months of age.
For combined therapy (planned after the results obtained with single-agent treatments), A3/3 and TIMP-2 constructs were administered i.t. with or without s.c. TAM and treatments were carried out until 6 months of age. Control mice received Corn Oil or DOSPER or nothing (three mice per group). In previous analyses, no difference was detected between these groups of control mice 12 and for this reason they were all grouped in the present work. For vessel density evaluation,samples from the heaviest and the lightest mammary tumors of each mouse were processed as previously described. 12 Three areas of 313179,68 mm 2 with very high vascularization ('hot spots') were chosen from each tumor and vessels were counted using an image analyzer (software Image Pro-Plus 4.5).
Statistical analysis
The statistical evaluation of the effect of different treatments on tumor weight and vessel density was carried out with one-tail Student's t-test. Comparison of the metastatization in combined therapy protocol was performed with the Fisher's exact test.
